McKesson (MCK) Projected to Post Earnings on Wednesday

McKesson (NYSE:MCK) will likely be releasing its Q3 2026 results after the market closes on Wednesday, February 4th. Analysts expect McKesson to post earnings of $9.19 per share and revenue of $105.9821 billion for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $9.86 EPS for the quarter, beating analysts’ consensus estimates of $8.84 by $1.02. The firm had revenue of $103.15 billion for the quarter, compared to analysts’ expectations of $103.80 billion. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $7.07 EPS. On average, analysts expect McKesson to post $33 EPS for the current fiscal year and $37 EPS for the next fiscal year.

McKesson Stock Performance

MCK stock opened at $831.32 on Monday. The stock has a fifty day moving average of $828.09 and a 200-day moving average of $774.41. McKesson has a fifty-two week low of $570.51 and a fifty-two week high of $895.58. The company has a market capitalization of $102.61 billion, a price-to-earnings ratio of 25.87, a PEG ratio of 1.37 and a beta of 0.40.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is currently 10.21%.

Insider Transactions at McKesson

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,851,096.24. This represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of McKesson stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $861.63, for a total transaction of $283,476.27. Following the transaction, the chief accounting officer directly owned 328 shares in the company, valued at $282,614.64. This trade represents a 50.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On McKesson

Several institutional investors and hedge funds have recently made changes to their positions in the business. Sunbelt Securities Inc. raised its position in McKesson by 3.6% in the 3rd quarter. Sunbelt Securities Inc. now owns 494 shares of the company’s stock worth $382,000 after purchasing an additional 17 shares during the period. ICONIQ Capital LLC grew its stake in shares of McKesson by 3.6% during the second quarter. ICONIQ Capital LLC now owns 715 shares of the company’s stock valued at $524,000 after buying an additional 25 shares during the last quarter. L2 Asset Management LLC increased its holdings in shares of McKesson by 5.1% in the third quarter. L2 Asset Management LLC now owns 580 shares of the company’s stock worth $448,000 after buying an additional 28 shares during the period. Prosperity Consulting Group LLC increased its holdings in shares of McKesson by 6.0% in the third quarter. Prosperity Consulting Group LLC now owns 510 shares of the company’s stock worth $394,000 after buying an additional 29 shares during the period. Finally, Modern Wealth Management LLC lifted its stake in shares of McKesson by 4.1% in the 2nd quarter. Modern Wealth Management LLC now owns 843 shares of the company’s stock valued at $618,000 after acquiring an additional 33 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

Analysts Set New Price Targets

MCK has been the topic of several research reports. Jefferies Financial Group boosted their price target on shares of McKesson from $820.00 to $900.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Barclays started coverage on shares of McKesson in a research note on Monday, December 8th. They issued an “overweight” rating and a $960.00 price objective for the company. Morgan Stanley restated an “overweight” rating and set a $966.00 target price on shares of McKesson in a research report on Thursday. Wall Street Zen cut McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “buy (a-)” rating on shares of McKesson in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, McKesson has a consensus rating of “Moderate Buy” and a consensus price target of $899.36.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.